JANX Q3 2021 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

JANXJanux Therapeutics, Inc.

$835M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M

Gross Profit

-$7M-625.3% margin

Operating Income

-$11M-940.7% margin

Net Income

-$11M-928.9% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+140.5%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$391M

Total Liabilities

$14M

Stockholders' Equity

$377M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$0	—
Gross Profit	-$7M	$0	—
Operating Income	-$11M	-$1M	-768.1%
Net Income	-$11M	-$1M	-757.2%